H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $102 from $81 and keeps a Buy rating on the shares. The company preannounced ‘impressive” preliminary financial results, the analyst tells investors in a research note. The firm sees a catalyst rich year for Mirum following its “bullish” guidance for 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum price target raised at Baird after preliminary results
- Mirum Pharmaceuticals price target raised to $95 from $88 at Baird
- Mirum Pharmaceuticals sees FY26 revenue $630M-$650M, consensus $595.94M
- Mirum Pharmaceuticals reports preliminary Q4 revenue $149M, consensus $135.72M
- Mirum Pharmaceuticals Announces Strong 2025 Sales and 2026 Outlook